Back Back
ESMO 2023 Highlights

CE / CME

Key Studies in Breast, Lung, Gastrointestinal, Genitourinary, and Skin Cancers: CCO Independent Conference Highlights of the 2023 ESMO Congress

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits™

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: December 22, 2023

Expiration: December 21, 2024

Natasha Leighl
Natasha Leighl, MD, MMSc, FRCPC, FASCO
Evan J. Lipson
Evan J. Lipson, MD
John Marshall
John Marshall, MD
Joyce O'Shaughnessy
Joyce O'Shaughnessy, MD
Daniel P. Petrylak
Daniel P. Petrylak, MD
CME/CE Information

Activity

Progress
1
Course Completed

Introduction

At the 2023 European Society for Medical Oncology (ESMO) annual congress in Madrid, Spain, new clinical trial data on breast, lung, gastrointestinal, genitourinary, and skin cancers were reported. In this module, Joyce O’Shaughnessy, MD; Natasha Leighl, MD, FRCPC, FASCO; John Marshall, MD; Daniel P. Petrylak, MD; and Evan J. Lipson, MD, review and discuss the clinical implications of key studies presented at the meeting.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with cancer do you provide care for in a typical month?

Which of the following solid tumor malignancies do you treat in your clinical practice?

You are discussing treatment options with your patient with recently diagnosed stage IV nonsquamous non-small-cell lung cancer with brain metastases. His molecular testing results indicate that his tumor is RET fusion positive. Which of the following would you tell him about the efficacy of selpercatinib compared with platinum-based chemotherapy with or without pembrolizumab based on evidence from the phase III LIBRETTO-431 trial?

Which of the following results was reported from the phase II TROPiCS-03 trial of sacituzumab govitecan in patients with extensive-stage small-cell lung cancer?

When discussing the data reported at ESMO 2023 from the phase III TROPION-Breast01 trial with your colleague, which of the following adverse events (AEs) would you indicate was most frequently observed in patients treated with datopotamab deruxtecan (Dato-DXd)?

Which of the following was the median progression-free survival (PFS) finding from the updated phase III CABINET trial analysis of cabozantinib vs placebo for patients with previously treated extrapancreatic neuroendocrine tumors (epNETs) and pancreatic neuroendocrine tumors (pNETs)?

You are discussing treatment options with your patient with recently diagnosed locally advanced urothelial carcinoma. Which of the following would you tell him about the efficacy of enfortumab vedotin plus pembrolizumab vs chemotherapy based on the EV-302/KEYNOTE-A39 trial reported by Powles and colleagues at ESMO 2023?

BACK | NEXT